Low paraoxonase-1 (PON1) activity has been regarded as one of risk factors for cardiovascular disease. We showed that low PON1 activity was independently associated with carotid intima-media thickness (IMT) and heart to femoral pulse wave velocity (hfPWV) in hypertensive patients. Our results indicate that PON1 activity may reflect early structural and functional changes of arteries in this population.
High-density lipoprotein has well-known protective effects against atherosclerosis, aiding reverse cholesterol transport from the artery wall and protecting low-density lipoprotein (LDL) against oxidation. 1 The antioxidant mechanisms of highdensity lipoprotein have been intensely studied, leading to the identification of paraoxonase-1 (PON1) as one of the major contributors.
2 PON1 prevents LDL oxidation by reducing lipid peroxides, enhances cholesterol efflux from macrophages and interrupts foam cell formation by suppressing oxidized LDL uptake by macrophages.
2 Some studies have reported that low PON1 activity could be one of the risk factors for cardiovascular disease. It has been further shown that reduced serum concentrations and activity of PON1 in patients with coronary artery disease relate to the severity of the disease. 3 In this study, we sought to identify a relationship between PON1 activity and carotid IMT, a surrogate marker of early atherosclerosis, in hypertensive patients. In addition, we evaluated the association between PON1 activity and arterial stiffness.
The study population consisted of 156 consecutive hypertensive patients treated at an outpatient clinic. We recruited patients who satisfied the criteria of systolic blood pressure (BP) greater than 140 mm Hg and/or diastolic BP greater than 90 mm Hg during three different visits before taking antihypertensive medication. We also included patients taking antihypertensive medications before enrolment.
Venous blood was sampled after an overnight fast, and the serum was immediately frozen at À70 1C for future analysis. Paraoxonase activity was measured in 5 ml of patient plasma, diluted to a final concentration of 2%, using the EnzCheck Paraoxonase Assay Kit (Molecular Probes, Invitrogen, Carlsbad, CA, USA). The intensity of emitted light was measured with a Victor2 plate reader (Perkin Elmer-Cetus Life Sciences, Boston, MA, USA) using 360 and 450 nm filters for excitation and emission, respectively. Enzymatic activity was calculated by converting fluorescent signals into activity using a standard curve. Activity was expressed as U per ml, where 1 unit of paraoxonase is defined as the amount of enzyme that liberates 1 nmole of organophosphate per min at 37 1C. An optimal longitudinal B-mode image of common carotid arteries proximal to the bifurcation was obtained by 8-MHz linear scanner (SequoiaC512, Acuson Co Ltd, Oceanside, CA, USA) and stored digitally. The mean carotid IMT of the far walls of the common carotid arteries were measured 1 cm proximal to the bifurcation on the end-diastolic frame using an automated edgedetection method programme (M'ATH, METRIS Co, Argenteuil, France). BP was measured in the dominant arm using a mercury sphygmomanometer after patients had been seated for at least 5 min. Pulse wave velocity was measured as previously reported. 4 Correlations between continuous variables were analysed by Pearson's correlation tests. A Spearman's correlation was used for variables that showed a skewed distribution. Independent determinants of mean carotid IMT and hfPWV were identified using multiple linear regression analysis. Statistical analyses were performed using SPSS 13.0 (SPSS Inc, Chicago, IL, USA). A P-value o0.05 was considered statistically significant.
A total of 48 patients (31%) had dyslipidemia, 30 of whom (19%) were taking statins. In total, 87 patients (56%) were taking a calcium channel blocker and 61 (39%) were taking an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker. The mean and maximum carotid IMTs were 0.68 ± 0.09 mm and 0.84 ± 0.11 mm, respectively, and the mean hfPWV was 1005±213 cm s
À1
. The mean PON1 activity was 10.0 ± 2.7 U ml À1 . There was a negative correlation between PON1 activity and mean carotid IMT (r ¼ À0.19, P ¼ 0.02).
Age, history of smoking and PON1 activity correlated with mean carotid IMT in univariate linear regression analyses. In a multiple linear regression analysis, PON1 activity remained as an independent determinant (b ¼ À0.19, P ¼ 0.02) after adjusting for age, gender, systolic BP and history of smoking (Table 1) . PON1 activity was negatively correlated with hfPWV (r ¼ À0.21, Po0.01). In univariate linear regression analyses, age, BP and PON1 activity were correlated with hfPWV. In a multiple linear regression analysis, PON1 activity was significantly associated with hfPWV (b ¼ À0.20, P ¼ 0.02) after adjusting for age, gender, LDL-cholesterol, statin medication and mean arterial pressure (Table 1) .
Atherosclerosis develops more progressively in Pon1 knockout mice than in wild-type mice, 5 whereas transgenic mice overexpressing PON1 exhibit a pronounced decrease in atherosclerotic plaque formation compared with wild-type mice. 6 More recently, PON1 has been shown to augment the levels of 7-ketocholesterol, which possesses antiatherogenic properties, by inhibiting 3-hydroxy-3-methyl-glutaryl-CoA reductase and 11b-hydroxysteroid dehydrogenase type 1. 7 Furthermore, PON1 hydrolyses homocystine-thiolactone, the chemically reactive form of homocysteine, which is involved in endothelial dysfunction and vascular damage. PON1 activity and concentration are lower in patients with coronary artery disease than in normal subjects and are correlated with the severity of coronary artery disease. 3 A study by Bhattacharyya et al. 9 showed that major cardiac adverse events were more frequent during follow-up in the group with lower PON1 activity. A few studies that have considered the relationship between PON1 and carotid IMT have focused on PON1 polymorphisms. 10 However, these studies have yielded conflicting results about the relationship between PON1 polymorphisms and cardiovascular risk. 9 Harangi et al.
11 reported a negative relationship between PON1 activity and carotid IMT, showing that total PON1 activity, salt-stimulated PON1 activity and arylesterase activity were negatively correlated with carotid IMT. However, 67% of the subjects in that study were with overt atherosclerosis (occlusive carotid artery disease). On the contrary, we confirmed the association between PON1 activity and carotid IMT in a population that excluded patients with overt atherosclerosis. Our result might present a possible role for PON1 in early atherosclerosis.
Arterial stiffness is influenced by elastic fiber degeneration, increased collagen and hypertrophy in vascular smooth muscle layers, all of which are related to oxidative stress. Brinkley et al. 12 reported that the level of oxidized LDL was a predictor of increased pulse wave velocity independent of traditional cardiovascular risk factors. In our study, we were able to show that PON1 activity was negatively associated with hfPWV even after adjusting for age, BP and lipid profiles. The significant association between reduced PON1 activity and stiffer arteries reported here might be explained, at least in part, by vascular changes associated with oxidative stress, as noted above.
Several limitations of our study should be noted. First, some important variables might not have achieved statistical significance because the number of patients was small. Second, some of our patients were taking medications that might potentially affect PON1 activity or atherosclerosis progression. Although we attempted to minimize such influences Research Letter through statistical analysis, it is possible that medication effects were not completely eliminated.
Third, PON1 has a number of enzymatic activities, acting as an organophosphatase, a phosphotriesterase and an arylesterase. At present, optimal target enzyme, reference method and reference substrates have not been standardized. In this study, we used the EnzChek Paraoxonase Assay from Invitrogen, which is a homogeneous fluorometric assay for the organophosphatase activity of paraoxonase. Although this assay is 10-fold more sensitive than the colorimetric paraoxon assay, a larger body of clinical data based on this method will ultimately be required to establish its general acceptance. In summary, reduced PON1 activity was independently related with carotid IMT. Furthermore, reduced PON1 activity was significantly associated with increased arterial stiffness. The results of this study show a possible role for PON1 in early atherosclerosis and vascular stiffness. Although this study was carried out using a relatively small number of patients, it is potentially significant because of the implication that PON1 activity may be involved in early structural and functional changes in hypertensive patients.
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